Aurinia Pharmaceuticals Inc reports results for the quarter ended in January 1 - Earnings Summary

• Aurinia Pharmaceuticals Inc AUPH.OQ reported quarterly adjusted earnings of 10 cents​​ per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of -9 cents. The mean expectation of six analysts for the quarter was for earnings of 2 cents per share. Wall Street expected results to range from -4 cents to 5 cents per share.

• Revenue rose 24.3% to $67.77 million from a year ago; analysts expected $57.69 million.

• Aurinia Pharmaceuticals Inc's reported EPS for the quarter was 10 cents​.

• The company reported quarterly net income of $14.35 million.

• Aurinia Pharmaceuticals Inc shares had risen by 2.6% this quarter and lost 16.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Aurinia Pharmaceuticals Inc is 10.00

This summary was machine generated from LSEG data November 7 at 02:38 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)